The thioredoxin system and cancer therapy: a review
Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These rep...
Uloženo v:
| Vydáno v: | Cancer chemotherapy and pharmacology Ročník 84; číslo 5; s. 925 - 935 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.11.2019
Springer Nature B.V |
| Témata: | |
| ISSN: | 0344-5704, 1432-0843, 1432-0843 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These reports indicated that many tumor cells express high levels of Trx and TrxR, which can be responsible for drug resistance in tumorigenesis. Inhibition of the Trx system may thus contribute to cancer therapy and improving chemotherapeutic agents. There are now a number of effective natural and synthetic inhibitors with chemotherapy applications possessing antitumor activity ranging from oxidative stress induction to apoptosis. In this article, we first described the features and functions of the Trx system and then reviewed briefly its correlations with cancer. Finally, we summarized the present knowledge about the Trx/TrxR inhibitors as anticancer drugs. |
|---|---|
| AbstractList | Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These reports indicated that many tumor cells express high levels of Trx and TrxR, which can be responsible for drug resistance in tumorigenesis. Inhibition of the Trx system may thus contribute to cancer therapy and improving chemotherapeutic agents. There are now a number of effective natural and synthetic inhibitors with chemotherapy applications possessing antitumor activity ranging from oxidative stress induction to apoptosis. In this article, we first described the features and functions of the Trx system and then reviewed briefly its correlations with cancer. Finally, we summarized the present knowledge about the Trx/TrxR inhibitors as anticancer drugs. Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These reports indicated that many tumor cells express high levels of Trx and TrxR, which can be responsible for drug resistance in tumorigenesis. Inhibition of the Trx system may thus contribute to cancer therapy and improving chemotherapeutic agents. There are now a number of effective natural and synthetic inhibitors with chemotherapy applications possessing antitumor activity ranging from oxidative stress induction to apoptosis. In this article, we first described the features and functions of the Trx system and then reviewed briefly its correlations with cancer. Finally, we summarized the present knowledge about the Trx/TrxR inhibitors as anticancer drugs.Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These reports indicated that many tumor cells express high levels of Trx and TrxR, which can be responsible for drug resistance in tumorigenesis. Inhibition of the Trx system may thus contribute to cancer therapy and improving chemotherapeutic agents. There are now a number of effective natural and synthetic inhibitors with chemotherapy applications possessing antitumor activity ranging from oxidative stress induction to apoptosis. In this article, we first described the features and functions of the Trx system and then reviewed briefly its correlations with cancer. Finally, we summarized the present knowledge about the Trx/TrxR inhibitors as anticancer drugs. |
| Author | Hashemy, Seyed Isaac Soltani, Arash Ghahremanloo, Atefeh Javid, Hossein Mohammadi, Fariba |
| Author_xml | – sequence: 1 givenname: Fariba surname: Mohammadi fullname: Mohammadi, Fariba organization: Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences – sequence: 2 givenname: Arash surname: Soltani fullname: Soltani, Arash organization: Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences – sequence: 3 givenname: Atefeh surname: Ghahremanloo fullname: Ghahremanloo, Atefeh organization: Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences – sequence: 4 givenname: Hossein surname: Javid fullname: Javid, Hossein organization: Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences – sequence: 5 givenname: Seyed Isaac orcidid: 0000-0002-1323-5250 surname: Hashemy fullname: Hashemy, Seyed Isaac email: hashemyi@mums.ac.ir organization: Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Surgical Oncology Research Center, Mashhad University of Medical Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31367788$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMtOAjEUQBuDUUB_wIWZxI2b0dvH0OLOGF8JiRtcN31cZAx0sB1U_t4qEBMWrJqm59zcnh7phCYgIWcUriiAvE4ATEEJdFgCH1JWigPSpYKzEpTgHdIFLkRZSRDHpJfSOwAIyvkROeaUD6RUqkv4eIpFO62biL75rkORVqnFeWGCL5wJDmN-xWgWq5vCFBE_a_w6IYcTM0t4ujn75PXhfnz3VI5eHp_vbkel47JqS-eVHTArRTW0zFfKGgNWMm9pvk88tY4ZrLyinFoOjgnBgGccrPMDVBXvk8v13EVsPpaYWj2vk8PZzARslkkzlj8hVCV5Ri920PdmGUPe7o9iUomhytT5hlraOXq9iPXcxJXe5siAWgMuNilFnGhXt6atm9BGU880Bf1bXq_L61xe_5XXIqtsR91O3yvxtZQyHN4w_q-9x_oBktSTQw |
| CitedBy_id | crossref_primary_10_1016_j_ijbiomac_2025_144791 crossref_primary_10_3390_ijms25094887 crossref_primary_10_3390_antiox13040475 crossref_primary_10_1002_cre2_364 crossref_primary_10_1007_s00210_023_02698_w crossref_primary_10_1002_cmdc_202100022 crossref_primary_10_1021_acscentsci_5c00816 crossref_primary_10_1016_j_lfs_2020_117403 crossref_primary_10_1155_2021_1383878 crossref_primary_10_3390_biom9110735 crossref_primary_10_3390_pharmaceutics16091208 crossref_primary_10_1016_j_phrs_2022_106113 crossref_primary_10_1016_j_bioorg_2021_104814 crossref_primary_10_1002_cmdc_202000138 crossref_primary_10_3390_ijms25084559 crossref_primary_10_1016_j_autrev_2025_103823 crossref_primary_10_3390_antiox12071331 crossref_primary_10_3390_antiox13091078 crossref_primary_10_1038_s41420_023_01720_7 crossref_primary_10_3390_pr9122100 crossref_primary_10_1016_j_ejphar_2025_178085 crossref_primary_10_2174_0118715206339230241202062826 crossref_primary_10_3390_cancers12071706 crossref_primary_10_1016_j_pestbp_2025_106390 crossref_primary_10_3390_molecules27165207 crossref_primary_10_1016_j_ejphar_2022_174756 crossref_primary_10_1016_j_heliyon_2024_e31864 crossref_primary_10_3390_diseases12100227 crossref_primary_10_3390_ijms23126557 crossref_primary_10_1016_j_cclet_2024_110727 crossref_primary_10_3390_antiox11101877 crossref_primary_10_1016_j_heliyon_2024_e27011 crossref_primary_10_3389_fcimb_2025_1659729 crossref_primary_10_1186_s40364_024_00593_x crossref_primary_10_3390_nano12183183 crossref_primary_10_1016_j_phrs_2021_105854 crossref_primary_10_1016_j_cbi_2023_110411 crossref_primary_10_3390_ijms25084505 crossref_primary_10_1016_j_polymertesting_2022_107746 crossref_primary_10_70322_jrbtm_2025_10006 crossref_primary_10_3390_ijms21228563 crossref_primary_10_1021_acs_orglett_5c03701 crossref_primary_10_1080_17501911_2024_2441652 crossref_primary_10_1002_chem_202103048 crossref_primary_10_1007_s11224_025_02518_2 crossref_primary_10_1016_j_nano_2023_102688 crossref_primary_10_1016_j_bcp_2025_116763 crossref_primary_10_1155_2022_8540403 crossref_primary_10_3390_pharmaceutics15020427 crossref_primary_10_3390_antiox14081002 crossref_primary_10_1016_j_drup_2021_100778 crossref_primary_10_3390_biomedicines10071757 crossref_primary_10_3390_pharmaceutics13071032 crossref_primary_10_1002_adfm_202004834 crossref_primary_10_1186_s10020_023_00700_y crossref_primary_10_4236_jbise_2025_188025 crossref_primary_10_3389_fphar_2021_625946 crossref_primary_10_3390_cancers14061531 crossref_primary_10_3390_pharmaceutics15061653 crossref_primary_10_3390_pr11113128 crossref_primary_10_1016_j_theriogenology_2024_04_005 crossref_primary_10_3390_ijms252212387 crossref_primary_10_1016_j_ccr_2024_216408 crossref_primary_10_2174_0109298673275187231121054541 crossref_primary_10_1080_13543776_2021_1899160 crossref_primary_10_3389_fmolb_2020_586146 crossref_primary_10_1007_s12672_021_00439_0 crossref_primary_10_3389_fmicb_2021_663481 crossref_primary_10_3390_life15040655 crossref_primary_10_1016_j_ijbiomac_2023_124509 crossref_primary_10_1038_s41598_019_55641_6 crossref_primary_10_1002_chem_202404029 crossref_primary_10_1016_j_bbrc_2022_12_045 crossref_primary_10_1016_j_taap_2024_116844 crossref_primary_10_1111_cpr_12781 crossref_primary_10_1186_s11658_021_00301_9 crossref_primary_10_3390_molecules29235672 crossref_primary_10_1016_j_redox_2020_101685 crossref_primary_10_3390_cancers16132319 crossref_primary_10_1155_2020_3216415 crossref_primary_10_1155_2021_6620708 crossref_primary_10_1016_j_brainresbull_2022_05_008 crossref_primary_10_1007_s10989_022_10399_w crossref_primary_10_3390_antiox9010055 |
| Cites_doi | 10.1073/pnas.87.21.8282 10.1074/jbc.274.39.27891 10.1634/theoncologist.12-10-1247 10.1038/sj.bjc.6603463 10.1182/blood-2004-04-1577 10.1016/j.abb.2003.12.026 10.1002/mnfr.200700492 10.1038/ncomms3958 10.1023/B:CBTO.0000004952.07979.3d 10.1074/jbc.M310292200 10.1111/j.0022-202X.2005.23925.x 10.1016/S0006-2952(97)00597-2 10.1093/jnci/92.15.1210 10.1021/cr980431o 10.1038/35106079 10.1073/pnas.0701549104 10.1200/jco.2004.22.14_suppl.3089 10.1074/jbc.272.49.30615 10.1016/j.bbabio.2013.11.007 10.1074/jbc.M511373200 10.1016/S0006-291X(05)81536-0 10.1038/nrd1691 10.1161/01.RES.0000022160.64355.62 10.1016/j.tiv.2006.01.012 10.1016/j.freeradbiomed.2005.02.026 10.1016/j.freeradbiomed.2006.12.021 10.1016/S0891-5849(01)00698-0 10.1089/ars.2012.4716 10.29252/nirp.cjns.3.11.206 10.1158/0008-5472.CAN-05-3310 10.1074/jbc.M414645200 10.1016/S0928-4680(00)00050-X 10.1179/135100001101536427 10.1002/med.10051 10.1002/jcb.20585 10.1007/s00432-006-0182-9 10.1073/pnas.182372299 10.1200/JCO.2005.10.217 10.1111/j.1749-6632.2003.tb05964.x 10.1188/02.CJON.341-346 10.1006/dbio.1996.0208 10.1021/bi051321w 10.1016/j.bcp.2007.04.007 10.1084/jem.189.11.1783 10.1016/S0891-5849(01)00724-9 10.1042/bj3460001 10.1073/pnas.231472998 10.1016/j.bcp.2003.09.038 10.1093/nar/20.15.3821 10.1016/j.coph.2007.04.003 10.1074/jbc.273.18.10835 10.1146/annurev.biophys.30.1.421 10.1016/j.freeradbiomed.2005.04.025 10.1371/journal.pbio.0030375 10.1146/annurev.immunol.15.1.351 10.1016/j.semcancer.2006.09.004 10.1016/j.abb.2004.04.020 10.1111/jop.12326 10.1016/j.redox.2017.09.014 10.1016/0167-4781(94)90180-5 10.1016/j.biochi.2012.05.012 10.1016/j.freeradbiomed.2010.09.005 10.1089/ars.2011.4322 10.1161/01.RES.0000130525.37646.a7 10.1517/13543784.13.1.21 10.3390/cancers2020209 10.1021/ic048260v 10.3109/10409238.2013.764840 10.1016/S1044-0305(03)00141-7 10.1073/pnas.0704898104 10.1182/blood.V88.3.1052.1052 10.1073/pnas.0408732102 10.1146/annurev.bi.54.070185.001321 10.1074/jbc.273.32.20096 10.1089/ars.2007.9.25 10.3748/wjg.v18.i39.5581 10.15171/jhp.2018.33 10.1126/science.281.5383.1680 10.1016/j.cbi.2005.12.009 10.1111/j.1749-6632.1999.tb07814.x 10.1089/152308604771978336 10.1002/ijc.23709 10.1016/j.lab.2005.09.001 10.1111/j.1346-8138.2006.00156.x 10.1093/emboj/17.9.2596 10.1158/1541-7786.MCR-07-0324 10.1089/ars.2005.7.1189 10.1038/sj.bjp.0704823 10.1016/j.bbagen.2009.01.014 10.1073/pnas.94.8.3633 10.1080/10715760500135391 10.1016/j.yexcr.2003.07.005 10.1016/j.bcp.2007.07.022 10.1074/jbc.274.50.35809 10.2174/092986710790226165 10.1073/pnas.95.6.3003 10.1080/15216540252774739 10.1002/biof.5520100220 10.1016/j.tips.2017.06.001 10.1074/jbc.M101760200 10.1177/0885066618823152 10.1007/s13402-018-00421-z 10.1002/jcb.28007 10.1155/2008/260146 10.4103/0973-1482.189229 10.1074/jbc.M512719200 10.1002/ptr.6236 10.1002/jcp.27192 10.1016/S0021-9258(18)35742-9 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag GmbH Germany, part of Springer Nature 2019 Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. |
| Copyright_xml | – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2019 – notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00280-019-03912-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-0843 |
| EndPage | 935 |
| ExternalDocumentID | 31367788 10_1007_s00280_019_03912_4 |
| Genre | Journal Article Review |
| GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c375t-cd8b62b7459b2d58baa0b72db19b2fd1bc2ae5d8131b30c244203b740bcd6e853 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 96 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000490601000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0344-5704 1432-0843 |
| IngestDate | Thu Oct 02 09:51:03 EDT 2025 Sat Nov 08 14:37:33 EST 2025 Thu Apr 03 07:02:09 EDT 2025 Tue Nov 18 21:52:08 EST 2025 Sat Nov 29 04:45:34 EST 2025 Fri Feb 21 02:33:15 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Oxidative stress Thioredoxin Thioredoxin reductase Cancer therapy Cancer |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-cd8b62b7459b2d58baa0b72db19b2fd1bc2ae5d8131b30c244203b740bcd6e853 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-1323-5250 |
| PMID | 31367788 |
| PQID | 2267278498 |
| PQPubID | 48447 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2267748573 proquest_journals_2267278498 pubmed_primary_31367788 crossref_citationtrail_10_1007_s00280_019_03912_4 crossref_primary_10_1007_s00280_019_03912_4 springer_journals_10_1007_s00280_019_03912_4 |
| PublicationCentury | 2000 |
| PublicationDate | 20191100 2019-11-00 2019-Nov 20191101 |
| PublicationDateYYYYMMDD | 2019-11-01 |
| PublicationDate_xml | – month: 11 year: 2019 text: 20191100 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Cancer chemotherapy and pharmacology |
| PublicationTitleAbbrev | Cancer Chemother Pharmacol |
| PublicationTitleAlternate | Cancer Chemother Pharmacol |
| PublicationYear | 2019 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Richon (CR105) 2006; 95 Milacic, Fregona, Dou (CR113) 2008; 23 Kim, Gladyshev (CR29) 2005; 3 Boroumand, Samarghandian, Hashemy (CR136) 2018; 7 CR39 Lu, Chew, Holmgren (CR86) 2007; 104 Hashemy, Ungerstedt, Avval, Holmgren (CR84) 2006; 281 Baker, Dragovich, Tate, Ramanathan, Roe, Hsu (CR93) 2006; 147 Lorestani, Hashemy, Mojarad, Keyvanloo Shahrestanaki, Bahari, Asadi (CR67) 2018; 9 Boulikas, Vougiouka (CR130) 2004; 11 Urig, Becker (CR131) 2006 Zhang, Richon, Ni, Talpur, Duvic (CR108) 2005; 125 Ueno, Masutani, Arai, Yamauchi, Hirota, Sakai (CR56) 1999; 274 Kang (CR36) 2002; 13 Powis, Kirkpatrick (CR55) 2007; 7 Piaz, Braca, Belisario, De Tommasi (CR139) 2010; 17 Lu, Papp, Fang, Rodriguez-Nieto, Zhivotovsky, Holmgren (CR134) 2006; 66 Zheng, Ma, Sun, Yin, Lin, Liu (CR78) 2018; 14 Kerimova, Atalay, Yusifov, Kuprin, Kerimov (CR111) 2000; 7 CR47 Matthews, Wakasugi, Virelizier, Yodoi, Hay (CR73) 1992; 20 Rigobello, Scutari, Folda, Bindoli (CR118) 2004; 67 Rhee, Chae, Kim (CR31) 2005; 38 Ceccarelli, Delfino, Zappia, Castellani, Borghi, Ferrini (CR71) 2008; 123 CR42 Valko, Rhodes, Moncol, Izakovic, Mazur (CR38) 2006; 160 CR41 Fang, Lu, Holmgren (CR138) 2005; 280 Marks, Rifkind, Richon, Breslow, Miller, Kelly (CR106) 2001; 1 Taheri, Tanipour, Khorasani, Kiafar, Layegh, Hashemy (CR44) 2016; 18 Ronconi, Giovagnini, Marzano, Bettìo, Graziani, Pilloni (CR114) 2005; 44 Farina, Tacconelli, Cappabianca, DeSantis, Gulino, Mackay (CR79) 2003; 291 Arner (CR16) 2009; 1790 Go, Jones (CR25) 2013; 48 Gan, Yang, Liu, Xu (CR77) 2005; 96 Welsh, Williams, Birmingham, Newman, Kirkpatrick, Powis (CR95) 2003; 2 Thannickal, Fanburg (CR2) 2000; 279 Fridovich (CR37) 1999; 893 Nakamura, Nakamura, Yodoi (CR75) 1997; 15 CR137 CR135 Nishinaka, Masutani, Nakamura, Yodoi (CR64) 2001; 6 Gallegos, Gasdaska, Taylor, Paine-Murrieta, Goodman, Gasdaska (CR72) 1996; 56 Matsui, Oshima, Oshima, Takaku, Maruyama, Yodoi (CR28) 1996; 178 Rosato, Grant (CR107) 2004; 13 Cenas, Nivinskas, Anusevicius, Sarlauskas, Lederer, Arnér (CR129) 2004; 279 Hirota, Murata, Sachi, Nakamura, Takeuchi, Mori (CR53) 1999; 274 Douer, Tallman (CR122) 2005; 23 Zhang, Liu, Kang, Seo, Rhee, Obeid (CR76) 1997; 272 Saitoh, Nishitoh, Fujii, Takeda, Tobiume, Sawada (CR48) 1998; 17 Lillig, Holmgren (CR18) 2007; 9 Rubartelli, Bajetto, Allavena, Wollman, Sitia (CR58) 1992; 267 Sengupta, Holmgren (CR32) 1820; 6 Pakfetrat, Dalirsani, Hashemy, Ghazi, Mostaan, Anvari (CR68) 2018; 14 Lee, Kim, Lee (CR17) 2013; 18 CR69 Oh, Chung, Steinbrenner, Sies, Brenneisen (CR12) 2004; 423 Seidel, Florean, Schnekenburger, Dicato, Diederich (CR97) 2012; 94 Dokmanovic, Clarke, Marks (CR99) 2007; 5 Mustacich, Powis (CR22) 2000; 346 Liu, Min (CR50) 2002; 90 Nordberg, Zhong, Holmgren, Arnér (CR87) 1998; 273 Tan, Bi, Zhang, Wang, Lin, Ni (CR91) 2014; 7 Powis, Montfort (CR35) 2001; 30 Mann, Johnson, Cohen, Justice, Pazdur (CR103) 2007; 12 Miller, Schipper, Lee, Singer, Waxman (CR125) 2002; 62 Gasdaska, Oblong, Cotgreave, Powis (CR4) 1994; 1218 Holmgren (CR19) 1985; 54 Arner, Holmgren (CR10) 2006 Kirkpatrick, Ehrmantraut, Stettner, Kunkel, Powis (CR92) 1997; 9 Thiagalingam, Cheng, Lee, Mineva, Thiagalingam, Ponte (CR100) 2003; 983 Nishiyama, Masutani, Nakamura, Nishinaka, Yodoi (CR65) 2001; 52 Ma, Caprioli, Hill, Burk (CR127) 2003; 14 Urig, Becker (CR15) 2006; 16 Welsh, Bellamy, Briehl, Powis (CR13) 2002; 62 Miranda-Vizuete, Ljung, Damdimopoulos, Gustafsson, Oko, Pelto-Huikko (CR24) 2001; 276 Tonissen, Di Trapani (CR14) 2009; 53 Butler, Zhou, Xu, Scher, Rifkind, Marks (CR83) 2002; 99 CR110 Karlenius, Tonissen (CR5) 2010; 2 Zhang, Li, Han, Liu, Fang (CR23) 2017; 38 Arnér, Nakamura, Sasada, Yodoi, Holmgren, Spyrou (CR133) 2001; 31 Raffel, Bhattacharyya, Gallegos, Cui, Einspahr, Alberts (CR9) 2003; 142 Sun, Su, Novoselov, Carlson, Hatfield, Gladyshev (CR27) 2005; 44 Sengupta, Holmgren (CR33) 2013; 18 Glaser (CR104) 2007; 74 Rigobello, Folda, Baldoin, Scutari, Bindoli (CR88) 2005; 39 Gromer, Arscott, Williams, Schirmer, Becker (CR115) 1998; 273 Mitchell, Morton, Fernhoff, Marletta (CR51) 2007; 104 Bizzarri, Holmgren, Pekkari, Chang, Colotta, Ghezzi (CR60) 2005; 7 Wang, Mayo, Korneluk, Goeddel, Baldwin (CR74) 1998; 281 Shoeibi, Razmi, Ghabeli Juibary, Hashemy (CR43) 2017; 3 CR124 Nakamura, Bai, Nishinaka, Ueda, Sasada, Ohshio (CR8) 2000; 24 Berggren, Gallegos, Gasdaska, Gasdaska, Warneke, Powis (CR81) 1996; 16 Lincoln, Ali, Tonissen, Clarke (CR80) 2003; 23 Holmgren, Sengupta (CR57) 2010; 49 Amirchaghmaghi, Hashemy, Alirezaei, Jahed Keyhani, Kargozar, Vasigh (CR46) 2016; 17 Kunkel, Kirkpatrick, Johnson, Powis (CR85) 1997; 12 Marzano, Gandin, Folda, Scutari, Bindoli, Rigobello (CR116) 2007; 42 Bertini, Howard, Dong, Oppenheim, Bizzarri, Sergi (CR59) 1999; 189 Moskovitz, Bar-Noy, Williams, Requena, Berlett, Stadtman (CR30) 2001; 98 Chen, Zhu, Shi, Ni, Zhong, Si (CR121) 1996; 88 Richon, Emiliani, Verdin, Webb, Breslow, Rifkind (CR102) 1998; 95 Marks, Richon, Rifkind (CR98) 2000; 92 Kim, Chae, Kim, Kim, Hwangs, Park (CR82) 2003; 19 Wang, Lippard (CR132) 2005; 4 Hirota, Matsui, Iwata, Nishiyama, Mori, Yodoi (CR54) 1997; 94 Shaw (CR112) 1999; 99 Cortassa, O’Rourke, Aon (CR3) 2014; 183 Pekkari, Goodarzi, Scheynius, Holmgren, Avila-Carino (CR61) 2005; 105 Witte, Anestål, Jerremalm, Ehrsson, Arnér (CR89) 2005; 39 Mayorga, Richardson-Hardin, Dicke (CR123) 2002; 6 Mitsui, Hirakawa, Yodoi (CR34) 1992; 186 Wang, Qin, Yi (CR101) 2015; 12 Arnér (CR128) 1999; 10 Terheyden, Kortüm, Schulze, Durani, Remling, Mauch (CR126) 2007; 133 Arnér, Holmgren (CR20) 2000; 267 Gromer, Urig, Becker (CR21) 2004; 24 Rackham, Nichols, Leedman, Berners-Price, Filipovska (CR119) 2007; 74 Zhang, Al-Lamki, Bai, Streb, Miano, Bradley (CR49) 2004; 94 Kirkpatrick, Kuperus, Dowdeswell, Potier, Donald, Kunkel (CR90) 1998; 55 CR26 Welsh, Williams, Birmingham, Newman, Kirkpatrick, Powis (CR94) 2003; 2 Chung, Jeon, Yoon, Choi (CR63) 2006; 33 Rigobello, Scutari, Boscolo, Bindoli (CR117) 2002; 136 Meuillet, Mahadevan, Berggren, Coon, Powis (CR52) 2004; 429 Nordberg, Arner (CR1) 2001; 31 Hwang, Suh, Jeon, Hwang, Nguyen, Yeom (CR62) 2014; 5 Lim, Yoon, Hong, Kim, Choi, Cho (CR7) 2012; 18 Peivandi Yazdi, Bameshki, Salehi, Kazemzadeh, Sharifian Razavi, Rahmani (CR40) 2018; 6 Rundlöf, Arnér (CR66) 2004; 6 Kawahara, Tanaka, Yokomizo, Nanri, Ono, Wada (CR6) 1996; 56 Wakasugi, Tagaya, Wakasugi, Mitsui, Maeda, Yodoi (CR70) 1990; 87 Ungerstedt, Sowa, Xu, Shao, Dokmanovic, Perez (CR109) 2005; 102 Omata, Folan, Shaw, Messer, Lockwood, Hobbs (CR120) 2006; 20 Farina, Tacconelli, Cappabianca, Masciulli, Holmgren, Beckett (CR11) 2001; 268 Hashemy, Gharaei, Vasigh, Kargozar, Alirezaei, Keyhani (CR45) 2016; 45 Kirkpatrick, Dragovich, Ramanathan, Sharlow, Chow, Williams (CR96) 2004; 22 N Cenas (3912_CR129) 2004; 279 A Taheri (3912_CR44) 2016; 18 EJ Meuillet (3912_CR52) 2004; 429 R Sengupta (3912_CR32) 1820; 6 A Mitsui (3912_CR34) 1992; 186 ES Arnér (3912_CR20) 2000; 267 cr-split#-3912_CR42.2 cr-split#-3912_CR42.1 Y Omata (3912_CR120) 2006; 20 AR Farina (3912_CR11) 2001; 268 SI Hashemy (3912_CR84) 2006; 281 PA Marks (3912_CR106) 2001; 1 L Ronconi (3912_CR114) 2005; 44 DL Kirkpatrick (3912_CR90) 1998; 55 S Lee (3912_CR17) 2013; 18 D Wang (3912_CR132) 2005; 4 I Fridovich (3912_CR37) 1999; 893 M Amirchaghmaghi (3912_CR46) 2016; 17 A Peivandi Yazdi (3912_CR40) 2018; 6 ES Arner (3912_CR16) 2009; 1790 LM Butler (3912_CR83) 2002; 99 JH Oh (3912_CR12) 2004; 423 JR Matthews (3912_CR73) 1992; 20 X Zheng (3912_CR78) 2018; 14 R Sengupta (3912_CR33) 2013; 18 AA Kerimova (3912_CR111) 2000; 7 3912_CR69 JY Lim (3912_CR7) 2012; 18 K Hirota (3912_CR53) 1999; 274 P Terheyden (3912_CR126) 2007; 133 SJ Welsh (3912_CR13) 2002; 62 VJ Thannickal (3912_CR2) 2000; 279 Jami Mayorga (3912_CR123) 2002; 6 J Hwang (3912_CR62) 2014; 5 J Fang (3912_CR138) 2005; 280 T Boulikas (3912_CR130) 2004; 11 S Cortassa (3912_CR3) 2014; 183 RR Rosato (3912_CR107) 2004; 13 A Gallegos (3912_CR72) 1996; 56 M Saitoh (3912_CR48) 1998; 17 F Piaz (3912_CR139) 2010; 17 HJ Kim (3912_CR82) 2003; 19 M Berggren (3912_CR81) 1996; 16 R Bertini (3912_CR59) 1999; 189 Y Tan (3912_CR91) 2014; 7 G Powis (3912_CR35) 2001; 30 C Zhang (3912_CR108) 2005; 125 S Thiagalingam (3912_CR100) 2003; 983 AF Baker (3912_CR93) 2006; 147 C Seidel (3912_CR97) 2012; 94 A-K Rundlöf (3912_CR66) 2004; 6 N Kawahara (3912_CR6) 1996; 56 M Dokmanovic (3912_CR99) 2007; 5 S Urig (3912_CR15) 2006; 16 AR Farina (3912_CR79) 2003; 291 N Wakasugi (3912_CR70) 1990; 87 (3912_CR131) 2006 A Miranda-Vizuete (3912_CR24) 2001; 276 (3912_CR10) 2006 PY Gasdaska (3912_CR4) 1994; 1218 D-H Kang (3912_CR36) 2002; 13 S Gromer (3912_CR21) 2004; 24 MP Rigobello (3912_CR118) 2004; 67 S Lorestani (3912_CR67) 2018; 9 A-B Witte (3912_CR89) 2005; 39 CF Shaw (3912_CR112) 1999; 99 MP Rigobello (3912_CR117) 2002; 136 G-Q Chen (3912_CR121) 1996; 88 J Moskovitz (3912_CR30) 2001; 98 P Zhang (3912_CR76) 1997; 272 A Shoeibi (3912_CR43) 2017; 3 JS Ungerstedt (3912_CR109) 2005; 102 SG Rhee (3912_CR31) 2005; 38 V Milacic (3912_CR113) 2008; 23 K Hirota (3912_CR54) 1997; 94 A Pakfetrat (3912_CR68) 2018; 14 SJ Welsh (3912_CR94) 2003; 2 J Nordberg (3912_CR87) 1998; 273 D Mustacich (3912_CR22) 2000; 346 DL Kirkpatrick (3912_CR92) 1997; 9 M Valko (3912_CR38) 2006; 160 SI Hashemy (3912_CR45) 2016; 45 3912_CR26 S Ma (3912_CR127) 2003; 14 N Boroumand (3912_CR136) 2018; 7 L Gan (3912_CR77) 2005; 96 3912_CR135 3912_CR137 J Raffel (3912_CR9) 2003; 142 MP Rigobello (3912_CR88) 2005; 39 G Powis (3912_CR55) 2007; 7 KB Glaser (3912_CR104) 2007; 74 D Douer (3912_CR122) 2005; 23 S Gromer (3912_CR115) 1998; 273 JW Chung (3912_CR63) 2006; 33 J Ceccarelli (3912_CR71) 2008; 123 BS Mann (3912_CR103) 2007; 12 ES Arnér (3912_CR128) 1999; 10 MW Kunkel (3912_CR85) 1997; 12 WH Miller (3912_CR125) 2002; 62 J Zhang (3912_CR23) 2017; 38 SJ Welsh (3912_CR95) 2003; 2 KF Tonissen (3912_CR14) 2009; 53 PA Marks (3912_CR98) 2000; 92 C Marzano (3912_CR116) 2007; 42 A Nishiyama (3912_CR65) 2001; 52 3912_CR124 3912_CR39 H Nakamura (3912_CR75) 1997; 15 M Ueno (3912_CR56) 1999; 274 J Nordberg (3912_CR1) 2001; 31 A Holmgren (3912_CR57) 2010; 49 C Bizzarri (3912_CR60) 2005; 7 ES Arnér (3912_CR133) 2001; 31 V Richon (3912_CR105) 2006; 95 J Lu (3912_CR86) 2007; 104 A Rubartelli (3912_CR58) 1992; 267 3912_CR41 A Holmgren (3912_CR19) 1985; 54 3912_CR110 J Lu (3912_CR134) 2006; 66 3912_CR47 Q-A Sun (3912_CR27) 2005; 44 R Zhang (3912_CR49) 2004; 94 HY Kim (3912_CR29) 2005; 3 L Kirkpatrick (3912_CR96) 2004; 22 Y Liu (3912_CR50) 2002; 90 DT Lincoln (3912_CR80) 2003; 23 Y Nishinaka (3912_CR64) 2001; 6 DA Mitchell (3912_CR51) 2007; 104 M Matsui (3912_CR28) 1996; 178 C-Y Wang (3912_CR74) 1998; 281 Z-Y Wang (3912_CR101) 2015; 12 TC Karlenius (3912_CR5) 2010; 2 H Nakamura (3912_CR8) 2000; 24 Y-M Go (3912_CR25) 2013; 48 CH Lillig (3912_CR18) 2007; 9 K Pekkari (3912_CR61) 2005; 105 VM Richon (3912_CR102) 1998; 95 O Rackham (3912_CR119) 2007; 74 |
| References_xml | – volume: 142 start-page: 46 issue: 1 year: 2003 end-page: 51 ident: CR9 article-title: Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival publication-title: Transl Res – volume: 87 start-page: 8282 issue: 21 year: 1990 end-page: 8286 ident: CR70 article-title: Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein–Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.87.21.8282 – volume: 274 start-page: 27891 issue: 39 year: 1999 end-page: 27897 ident: CR53 article-title: Distinct roles of thioredoxin in the cytoplasm and in the nucleus a two-step mechanism of redox regulation of transcription factor NF-κB publication-title: J Biol Chem doi: 10.1074/jbc.274.39.27891 – volume: 12 start-page: 1247 issue: 10 year: 2007 end-page: 1252 ident: CR103 article-title: FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma publication-title: Oncologist doi: 10.1634/theoncologist.12-10-1247 – volume: 95 start-page: S2 issue: S1 year: 2006 ident: CR105 article-title: Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603463 – volume: 105 start-page: 1598 issue: 4 year: 2005 end-page: 1605 ident: CR61 article-title: Truncated thioredoxin (Trx80) induces differentiation of human CD14+ monocytes into a novel cell type (TAMs) via activation of the MAP kinases p38, ERK, and JNK publication-title: Blood doi: 10.1182/blood-2004-04-1577 – volume: 268 start-page: 405 issue: 2 year: 2001 end-page: 413 ident: CR11 article-title: Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion publication-title: FEBS J – volume: 423 start-page: 218 issue: 1 year: 2004 end-page: 226 ident: CR12 article-title: Thioredoxin secreted upon ultraviolet A irradiation modulates activities of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in human dermal fibroblasts publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2003.12.026 – volume: 53 start-page: 87 issue: 1 year: 2009 end-page: 103 ident: CR14 article-title: Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.200700492 – volume: 6 start-page: 312 issue: 4 year: 2018 end-page: 317 ident: CR40 article-title: The effect of spinal and general anesthesia on serum lipid peroxides and total antioxidant capacity in diabetic patients with lower limb amputation surgery publication-title: Arch Bone Jt Surg – volume: 24 start-page: 53 issue: 1 year: 2000 end-page: 60 ident: CR8 article-title: Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer publication-title: Cancer Detect Prev – ident: CR39 – volume: 5 start-page: 2958 year: 2014 ident: CR62 article-title: The structural basis for the negative regulation of thioredoxin by thioredoxin-interacting protein publication-title: Nat Commun doi: 10.1038/ncomms3958 – ident: CR135 – volume: 19 start-page: 285 issue: 5 year: 2003 end-page: 298 ident: CR82 article-title: Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues publication-title: Cell Biol Toxicol doi: 10.1023/B:CBTO.0000004952.07979.3d – volume: 279 start-page: 2583 issue: 4 year: 2004 end-page: 2592 ident: CR129 article-title: Interactions of quinones with thioredoxin reductase a challenge to the antioxidant role of the mammalian selenoprotein publication-title: J Biol Chem doi: 10.1074/jbc.M310292200 – ident: CR42 – volume: 125 start-page: 1045 issue: 5 year: 2005 end-page: 1052 ident: CR108 article-title: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action publication-title: J Investig Dermatol doi: 10.1111/j.0022-202X.2005.23925.x – volume: 55 start-page: 987 issue: 7 year: 1998 end-page: 994 ident: CR90 article-title: Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(97)00597-2 – volume: 9 start-page: 351 issue: 6–7 year: 1997 end-page: 356 ident: CR92 article-title: Redox active disulfides: the thioredoxin system as a drug target publication-title: Oncol Res Featur Preclin Clin Cancer Ther – volume: 92 start-page: 1210 issue: 15 year: 2000 end-page: 1216 ident: CR98 article-title: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.15.1210 – volume: 99 start-page: 2589 issue: 9 year: 1999 end-page: 2600 ident: CR112 article-title: Gold-based therapeutic agents publication-title: Chem Rev doi: 10.1021/cr980431o – volume: 1 start-page: 194 issue: 3 year: 2001 ident: CR106 article-title: Histone deacetylases and cancer: causes and therapies publication-title: Nat Rev Cancer doi: 10.1038/35106079 – volume: 104 start-page: 12288 issue: 30 year: 2007 end-page: 12293 ident: CR86 article-title: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0701549104 – volume: 22 start-page: 3089 issue: 14_suppl year: 2004 ident: CR96 article-title: Results from phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies publication-title: J Clin Oncol doi: 10.1200/jco.2004.22.14_suppl.3089 – volume: 272 start-page: 30615 issue: 49 year: 1997 end-page: 30618 ident: CR76 article-title: Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2 publication-title: J Biol Chem doi: 10.1074/jbc.272.49.30615 – volume: 183 start-page: 287 issue: 2 year: 2014 end-page: 295 ident: CR3 article-title: Redox-optimized ROS balance and the relationship between mitochondrial respiration and ROS publication-title: Biochim Biophys Acta doi: 10.1016/j.bbabio.2013.11.007 – volume: 2 start-page: 235 issue: 3 year: 2003 end-page: 243 ident: CR94 article-title: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation publication-title: Mol Cancer Ther – volume: 281 start-page: 10691 issue: 16 year: 2006 end-page: 10697 ident: CR84 article-title: Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase publication-title: J Biol Chem doi: 10.1074/jbc.M511373200 – volume: 186 start-page: 1220 issue: 3 year: 1992 end-page: 1226 ident: CR34 article-title: Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(05)81536-0 – volume: 4 start-page: 307 issue: 4 year: 2005 ident: CR132 article-title: Cellular processing of platinum anticancer drugs publication-title: Nat Rev Drug Discov doi: 10.1038/nrd1691 – volume: 90 start-page: 1259 issue: 12 year: 2002 end-page: 1266 ident: CR50 article-title: Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner publication-title: Circ Res doi: 10.1161/01.RES.0000022160.64355.62 – volume: 20 start-page: 882 issue: 6 year: 2006 end-page: 890 ident: CR120 article-title: Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1) publication-title: Toxicol In Vitro doi: 10.1016/j.tiv.2006.01.012 – volume: 38 start-page: 1543 issue: 12 year: 2005 end-page: 1552 ident: CR31 article-title: Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling publication-title: Free Radical Biol Med doi: 10.1016/j.freeradbiomed.2005.02.026 – volume: 42 start-page: 872 issue: 6 year: 2007 end-page: 881 ident: CR116 article-title: Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2006.12.021 – volume: 31 start-page: 1170 issue: 10 year: 2001 end-page: 1178 ident: CR133 article-title: Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex publication-title: Free Radic Biol Med doi: 10.1016/S0891-5849(01)00698-0 – volume: 62 start-page: 5089 issue: 17 year: 2002 end-page: 5095 ident: CR13 article-title: The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis publication-title: Cancer Res – volume: 18 start-page: 259 issue: 3 year: 2013 end-page: 269 ident: CR33 article-title: Thioredoxin and thioredoxin reductase in relation to reversible S-nitrosylation publication-title: Antioxid Redox Signal doi: 10.1089/ars.2012.4716 – volume: 3 start-page: 206 issue: 11 year: 2017 end-page: 213 ident: CR43 article-title: The evaluation and comparison of oxidative stress in hemorrhagic and ischemic stroke publication-title: Casp J Neurol Sci doi: 10.29252/nirp.cjns.3.11.206 – ident: CR47 – volume: 66 start-page: 4410 issue: 8 year: 2006 end-page: 4418 ident: CR134 article-title: Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3310 – volume: 280 start-page: 25284 issue: 26 year: 2005 end-page: 25290 ident: CR138 article-title: Thioredoxin reductase is irreversibly modified by curcumin a novel molecular mechanism for its anticancer activity publication-title: J Biol Chem doi: 10.1074/jbc.M414645200 – volume: 7 start-page: 209 issue: 3 year: 2000 end-page: 213 ident: CR111 article-title: Antioxidant enzymes; possible mechanism of gold compound treatment in rheumatoid arthritis publication-title: Pathophysiology doi: 10.1016/S0928-4680(00)00050-X – volume: 56 start-page: 5765 issue: 24 year: 1996 end-page: 5770 ident: CR72 article-title: Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells publication-title: Cancer Res – volume: 56 start-page: 5330 issue: 23 year: 1996 end-page: 5333 ident: CR6 article-title: Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin publication-title: Cancer Res – volume: 6 start-page: 289 issue: 5 year: 2001 end-page: 295 ident: CR64 article-title: Regulatory roles of thioredoxin in oxidative stress-induced cellular responses publication-title: Redox Rep doi: 10.1179/135100001101536427 – volume: 24 start-page: 40 issue: 1 year: 2004 end-page: 89 ident: CR21 article-title: The thioredoxin system—from science to clinic publication-title: Med Res Rev doi: 10.1002/med.10051 – ident: CR137 – volume: 96 start-page: 653 issue: 3 year: 2005 end-page: 664 ident: CR77 article-title: Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells publication-title: J Cell Biochem doi: 10.1002/jcb.20585 – volume: 133 start-page: 437 issue: 7 year: 2007 end-page: 444 ident: CR126 article-title: Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-006-0182-9 – volume: 17 start-page: 21 issue: 1 year: 2016 end-page: 25 ident: CR46 article-title: Evaluation of plasma isoprostane in patients with oral lichen planus publication-title: J Dent – volume: 99 start-page: 11700 issue: 18 year: 2002 end-page: 11705 ident: CR83 article-title: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.182372299 – volume: 23 start-page: 2396 issue: 10 year: 2005 end-page: 2410 ident: CR122 article-title: Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies publication-title: J Clin Oncol doi: 10.1200/JCO.2005.10.217 – volume: 983 start-page: 84 issue: 1 year: 2003 end-page: 100 ident: CR100 article-title: Histone deacetylases: unique players in shaping the epigenetic histone code publication-title: Ann NY Acad Sci doi: 10.1111/j.1749-6632.2003.tb05964.x – ident: CR69 – volume: 6 start-page: 341 issue: 6 year: 2002 end-page: 346 ident: CR123 article-title: Arsenic Trioxide as Effective Therapy for Relapsed Acute Promyelocytic Leukemia publication-title: Clinical Journal of Oncology Nursing doi: 10.1188/02.CJON.341-346 – volume: 178 start-page: 179 issue: 1 year: 1996 end-page: 185 ident: CR28 article-title: Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene publication-title: Dev Biol doi: 10.1006/dbio.1996.0208 – volume: 44 start-page: 14528 issue: 44 year: 2005 end-page: 14537 ident: CR27 article-title: Reaction mechanism and regulation of mammalian thioredoxin/glutathione reductase publication-title: Biochemistry doi: 10.1021/bi051321w – volume: 74 start-page: 659 issue: 5 year: 2007 end-page: 671 ident: CR104 article-title: HDAC inhibitors: clinical update and mechanism-based potential publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2007.04.007 – volume: 6 start-page: 689 year: 1820 end-page: 700 ident: CR32 article-title: The role of thioredoxin in the regulation of cellular processes by S-nitrosylation publication-title: Biochim Biophysica Acta – volume: 189 start-page: 1783 issue: 11 year: 1999 end-page: 1789 ident: CR59 article-title: Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells publication-title: J Exp Med doi: 10.1084/jem.189.11.1783 – volume: 31 start-page: 1287 issue: 11 year: 2001 end-page: 1312 ident: CR1 article-title: Reactive oxygen species, antioxidants, and the mammalian thioredoxin system1 publication-title: Free Radic Biol Med doi: 10.1016/S0891-5849(01)00724-9 – volume: 346 start-page: 1 issue: Pt 1 year: 2000 end-page: 8 ident: CR22 article-title: Thioredoxin reductase publication-title: Biochem J doi: 10.1042/bj3460001 – volume: 98 start-page: 12920 issue: 23 year: 2001 end-page: 12925 ident: CR30 article-title: Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.231472998 – volume: 7 start-page: 4765 issue: 8 year: 2014 ident: CR91 article-title: Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide publication-title: Int J Clin Exp Pathol – volume: 67 start-page: 689 issue: 4 year: 2004 end-page: 696 ident: CR118 article-title: Mitochondrial thioredoxin reductase inhibition by gold (I) compounds and concurrent stimulation of permeability transition and release of cytochrome c publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2003.09.038 – volume: 20 start-page: 3821 issue: 15 year: 1992 end-page: 3830 ident: CR73 article-title: Thiordoxin regulates the DNA binding activity of NF-χB by reduction of a disulphid bond involving cysteine 62 publication-title: Nucl Acids Res doi: 10.1093/nar/20.15.3821 – volume: 23 start-page: 2425 issue: 3B year: 2003 end-page: 2433 ident: CR80 article-title: The thioredoxin-thioredoxin reductase system: over-expression in human cancer publication-title: Anticancer Res – ident: CR41 – volume: 7 start-page: 392 issue: 4 year: 2007 end-page: 397 ident: CR55 article-title: Thioredoxin signaling as a target for cancer therapy publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2007.04.003 – volume: 273 start-page: 10835 issue: 18 year: 1998 end-page: 10842 ident: CR87 article-title: Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue publication-title: J Biol Chem doi: 10.1074/jbc.273.18.10835 – volume: 23 start-page: 101 issue: 1 year: 2008 end-page: 108 ident: CR113 article-title: Gold complexes as prospective metal-based anticancer drugs publication-title: Histol Histopathol – volume: 30 start-page: 421 issue: 1 year: 2001 end-page: 455 ident: CR35 article-title: Properties and biological activities of thioredoxins publication-title: Annu Rev Biophys Biomol Struct doi: 10.1146/annurev.biophys.30.1.421 – volume: 39 start-page: 696 issue: 5 year: 2005 end-page: 703 ident: CR89 article-title: Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2005.04.025 – volume: 3 start-page: e375 issue: 12 year: 2005 ident: CR29 article-title: Different catalytic mechanisms in mammalian selenocysteine- and cysteine-containing methionine-R-sulfoxide reductases publication-title: PLoS Biol doi: 10.1371/journal.pbio.0030375 – volume: 15 start-page: 351 year: 1997 end-page: 369 ident: CR75 article-title: Redox regulation of cellular activation publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.15.1.351 – volume: 16 start-page: 452 issue: 6 year: 2006 end-page: 465 ident: CR15 article-title: On the potential of thioredoxin reductase inhibitors for cancer therapy publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2006.09.004 – volume: 429 start-page: 123 issue: 2 year: 2004 end-page: 133 ident: CR52 article-title: Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN’s tumor suppressor activity publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2004.04.020 – volume: 279 start-page: L1005 issue: 6 year: 2000 end-page: L1028 ident: CR2 article-title: Reactive oxygen species in cell signaling publication-title: Am J Phys Lung Cell Mol Phys – volume: 16 start-page: 3459 issue: 6B year: 1996 end-page: 3466 ident: CR81 article-title: Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia publication-title: Anticancer Res – year: 2006 ident: CR10 publication-title: The thioredoxin system in cancer. Seminars in cancer biology – volume: 45 start-page: 35 issue: 1 year: 2016 end-page: 40 ident: CR45 article-title: Oxidative stress factors and C-reactive protein in patients with oral lichen planus before and 2 weeks after treatment publication-title: J Oral Pathol Med doi: 10.1111/jop.12326 – volume: 14 start-page: 237 year: 2018 end-page: 249 ident: CR78 article-title: Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity publication-title: Redox Biol doi: 10.1016/j.redox.2017.09.014 – volume: 11 start-page: 559 issue: 3 year: 2004 end-page: 595 ident: CR130 article-title: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs publication-title: Oncol Rep – volume: 1218 start-page: 292 issue: 3 year: 1994 end-page: 296 ident: CR4 article-title: The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors publication-title: Biochim Biophys Acta doi: 10.1016/0167-4781(94)90180-5 – volume: 94 start-page: 2264 issue: 11 year: 2012 end-page: 2279 ident: CR97 article-title: Chromatin-modifying agents in anti-cancer therapy publication-title: Biochimie doi: 10.1016/j.biochi.2012.05.012 – volume: 49 start-page: 1617 issue: 11 year: 2010 end-page: 1628 ident: CR57 article-title: The use of thiols by ribonucleotide reductase publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2010.09.005 – volume: 2 start-page: 235 issue: 3 year: 2003 end-page: 243 ident: CR95 article-title: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation 1 publication-title: Mol Cancer Ther – volume: 18 start-page: 1165 issue: 10 year: 2013 end-page: 1207 ident: CR17 article-title: Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance publication-title: Antioxid Redox Signal doi: 10.1089/ars.2011.4322 – volume: 14 start-page: 428 issue: 2 year: 2018 end-page: 431 ident: CR68 article-title: Evaluation of serum levels of oxidized and reduced glutathione and total antioxidant capacity in patients with head and neck squamous cell carcinoma publication-title: J Cancer Res Ther – volume: 94 start-page: 1483 issue: 11 year: 2004 end-page: 1491 ident: CR49 article-title: Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner publication-title: Circ Res doi: 10.1161/01.RES.0000130525.37646.a7 – volume: 13 start-page: 21 issue: 1 year: 2004 end-page: 38 ident: CR107 article-title: Histone deacetylase inhibitors in clinical development publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.13.1.21 – volume: 2 start-page: 209 issue: 2 year: 2010 end-page: 232 ident: CR5 article-title: Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation publication-title: Cancers doi: 10.3390/cancers2020209 – volume: 44 start-page: 1867 issue: 6 year: 2005 end-page: 1881 ident: CR114 article-title: Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity publication-title: Inorg Chem doi: 10.1021/ic048260v – volume: 48 start-page: 173 issue: 2 year: 2013 end-page: 181 ident: CR25 article-title: Thiol/disulfide redox states in signaling and sensing publication-title: Crit Rev Biochem Mol Biol doi: 10.3109/10409238.2013.764840 – ident: CR26 – volume: 14 start-page: 593 issue: 6 year: 2003 end-page: 600 ident: CR127 article-title: Loss of selenium from selenoproteins: conversion of selenocysteine to dehydroalanine in vitro publication-title: J Am Soc Mass Spectrom doi: 10.1016/S1044-0305(03)00141-7 – volume: 104 start-page: 11609 issue: 28 year: 2007 end-page: 11614 ident: CR51 article-title: Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0704898104 – volume: 88 start-page: 1052 issue: 3 year: 1996 end-page: 1061 ident: CR121 article-title: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: as2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins publication-title: Blood doi: 10.1182/blood.V88.3.1052.1052 – volume: 102 start-page: 673 issue: 3 year: 2005 end-page: 678 ident: CR109 article-title: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0408732102 – volume: 54 start-page: 237 issue: 1 year: 1985 end-page: 271 ident: CR19 article-title: Thioredoxin publication-title: Annu Rev Biochem doi: 10.1146/annurev.bi.54.070185.001321 – volume: 12 start-page: 153 issue: 2 year: 2015 ident: CR101 article-title: Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease publication-title: J Geriatr Cardiol – volume: 13 start-page: 540 issue: 4 year: 2002 end-page: 549 ident: CR36 article-title: Oxidative stress, DNA damage, and breast cancer publication-title: AACN Adv Crit Care – volume: 267 start-page: 24161 issue: 34 year: 1992 end-page: 24164 ident: CR58 article-title: Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway publication-title: J Biol Chem – volume: 273 start-page: 20096 issue: 32 year: 1998 end-page: 20101 ident: CR115 article-title: Human placenta thioredoxin reductase isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds publication-title: J Biol Chem doi: 10.1074/jbc.273.32.20096 – volume: 9 start-page: 25 issue: 1 year: 2007 end-page: 47 ident: CR18 article-title: Thioredoxin and related molecules—from biology to health and disease publication-title: Antioxid Redox Signal doi: 10.1089/ars.2007.9.25 – volume: 18 start-page: 5581 issue: 39 year: 2012 ident: CR7 article-title: Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence publication-title: World J Gastroenterol doi: 10.3748/wjg.v18.i39.5581 – volume: 18 start-page: 156 issue: 4 year: 2016 end-page: 162 ident: CR44 article-title: Serum protein carbonyl and total antioxidant capacity levels in pemphigus vulgaris and bullous pemphigoid publication-title: Iran J Dermatol – volume: 7 start-page: 211 issue: 4 year: 2018 end-page: 219 ident: CR136 article-title: Immunomodulatory, anti-inflammatory, and antioxidant effects of curcumin publication-title: J Herbmed Pharmacol doi: 10.15171/jhp.2018.33 – volume: 281 start-page: 1680 issue: 5383 year: 1998 end-page: 1683 ident: CR74 article-title: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation publication-title: Science doi: 10.1126/science.281.5383.1680 – volume: 160 start-page: 1 issue: 1 year: 2006 end-page: 40 ident: CR38 article-title: Free radicals, metals and antioxidants in oxidative stress-induced cancer publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2005.12.009 – volume: 267 start-page: 6102 issue: 20 year: 2000 end-page: 6109 ident: CR20 article-title: Physiological functions of thioredoxin and thioredoxin reductase publication-title: FEBS J – volume: 12 start-page: 659 issue: 8 year: 1997 end-page: 670 ident: CR85 article-title: Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs publication-title: Anticancer Drug Des – volume: 893 start-page: 13 issue: 1 year: 1999 end-page: 18 ident: CR37 article-title: Fundamental aspects of reactive oxygen species, or what’s the matter with oxygen? publication-title: Ann NY Acad Sci doi: 10.1111/j.1749-6632.1999.tb07814.x – volume: 62 start-page: 3893 issue: 14 year: 2002 end-page: 3903 ident: CR125 article-title: Mechanisms of action of arsenic trioxide publication-title: Cancer Res – volume: 6 start-page: 41 issue: 1 year: 2004 end-page: 52 ident: CR66 article-title: Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events publication-title: Antioxid Redox Signal doi: 10.1089/152308604771978336 – volume: 123 start-page: 1770 issue: 8 year: 2008 end-page: 1778 ident: CR71 article-title: The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants publication-title: Int J Cancer doi: 10.1002/ijc.23709 – volume: 147 start-page: 83 issue: 2 year: 2006 end-page: 90 ident: CR93 article-title: The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma publication-title: J Lab Clin Med doi: 10.1016/j.lab.2005.09.001 – volume: 33 start-page: 662 issue: 10 year: 2006 end-page: 669 ident: CR63 article-title: Vitamin D3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases publication-title: J Dermatol doi: 10.1111/j.1346-8138.2006.00156.x – volume: 9 start-page: 99 issue: 2 year: 2018 end-page: 104 ident: CR67 article-title: Increased glutathione reductase expression and activity in colorectal cancer tissue samples: an investigational study in Mashhad publication-title: Iran Middle East J Cancer – ident: CR124 – volume: 17 start-page: 2596 issue: 9 year: 1998 end-page: 2606 ident: CR48 article-title: Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1 publication-title: EMBO J doi: 10.1093/emboj/17.9.2596 – volume: 5 start-page: 981 issue: 10 year: 2007 end-page: 989 ident: CR99 article-title: Histone deacetylase inhibitors: overview and perspectives publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-07-0324 – year: 2006 ident: CR131 publication-title: On the potential of thioredoxin reductase inhibitors for cancer therapy. Seminars in cancer biology – volume: 7 start-page: 1189 issue: 9–10 year: 2005 end-page: 1194 ident: CR60 article-title: Requirements for the different cysteines in the chemotactic and desensitizing activity of human thioredoxin publication-title: Antioxid Redox Signal doi: 10.1089/ars.2005.7.1189 – volume: 136 start-page: 1162 issue: 8 year: 2002 end-page: 1168 ident: CR117 article-title: Induction of mitochondrial permeability transition by auranofin, a Gold (I)-phosphine derivative publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0704823 – volume: 1790 start-page: 495 issue: 6 year: 2009 end-page: 526 ident: CR16 article-title: Focus on mammalian thioredoxin reductases—important selenoproteins with versatile functions publication-title: Biochem Biophys Acta doi: 10.1016/j.bbagen.2009.01.014 – volume: 94 start-page: 3633 issue: 8 year: 1997 end-page: 3638 ident: CR54 article-title: AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.94.8.3633 – volume: 39 start-page: 687 issue: 7 year: 2005 end-page: 695 ident: CR88 article-title: Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase publication-title: Free Radic Res doi: 10.1080/10715760500135391 – volume: 291 start-page: 474 issue: 2 year: 2003 end-page: 483 ident: CR79 article-title: Thioredoxin inhibits microvascular endothelial capillary tubule formation publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2003.07.005 – volume: 74 start-page: 992 issue: 7 year: 2007 end-page: 1002 ident: CR119 article-title: A gold (I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2007.07.022 – volume: 274 start-page: 35809 issue: 50 year: 1999 end-page: 35815 ident: CR56 article-title: Thioredoxin-dependent redox regulation of p53-mediated p21 activation publication-title: J Biol Chem doi: 10.1074/jbc.274.50.35809 – volume: 17 start-page: 479 issue: 5 year: 2010 end-page: 494 ident: CR139 article-title: Thioredoxin system modulation by plant and fungal secondary metabolites publication-title: Curr Med Chem doi: 10.2174/092986710790226165 – volume: 95 start-page: 3003 issue: 6 year: 1998 end-page: 3007 ident: CR102 article-title: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.95.6.3003 – volume: 52 start-page: 29 issue: 1 year: 2001 end-page: 33 ident: CR65 article-title: Redox regulation by thioredoxin and thioredoxin-binding proteins publication-title: IUBMB Life doi: 10.1080/15216540252774739 – ident: CR110 – volume: 10 start-page: 219 issue: 2–3 year: 1999 end-page: 226 ident: CR128 article-title: Superoxide production by dinitrophenyl-derivatized thioredoxin reductase–a model for the mechanism and correlation to immunostimulation by dinitrohalobenzenes publication-title: BioFactors doi: 10.1002/biof.5520100220 – volume: 38 start-page: 794 issue: 9 year: 2017 end-page: 808 ident: CR23 article-title: Targeting the thioredoxin system for cancer therapy publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2017.06.001 – volume: 276 start-page: 31567 issue: 34 year: 2001 end-page: 31574 ident: CR24 article-title: Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa publication-title: J Biol Chem doi: 10.1074/jbc.M101760200 – volume: 186 start-page: 1220 issue: 3 year: 1992 ident: 3912_CR34 publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(05)81536-0 – volume: 33 start-page: 662 issue: 10 year: 2006 ident: 3912_CR63 publication-title: J Dermatol doi: 10.1111/j.1346-8138.2006.00156.x – volume: 9 start-page: 99 issue: 2 year: 2018 ident: 3912_CR67 publication-title: Iran Middle East J Cancer – volume: 20 start-page: 882 issue: 6 year: 2006 ident: 3912_CR120 publication-title: Toxicol In Vitro doi: 10.1016/j.tiv.2006.01.012 – volume: 6 start-page: 289 issue: 5 year: 2001 ident: 3912_CR64 publication-title: Redox Rep doi: 10.1179/135100001101536427 – volume: 30 start-page: 421 issue: 1 year: 2001 ident: 3912_CR35 publication-title: Annu Rev Biophys Biomol Struct doi: 10.1146/annurev.biophys.30.1.421 – volume: 279 start-page: 2583 issue: 4 year: 2004 ident: 3912_CR129 publication-title: J Biol Chem doi: 10.1074/jbc.M310292200 – ident: 3912_CR39 doi: 10.1177/0885066618823152 – volume: 23 start-page: 2396 issue: 10 year: 2005 ident: 3912_CR122 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.10.217 – volume: 6 start-page: 341 issue: 6 year: 2002 ident: 3912_CR123 publication-title: Clinical Journal of Oncology Nursing doi: 10.1188/02.CJON.341-346 – volume: 38 start-page: 794 issue: 9 year: 2017 ident: 3912_CR23 publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2017.06.001 – volume: 38 start-page: 1543 issue: 12 year: 2005 ident: 3912_CR31 publication-title: Free Radical Biol Med doi: 10.1016/j.freeradbiomed.2005.02.026 – volume: 56 start-page: 5330 issue: 23 year: 1996 ident: 3912_CR6 publication-title: Cancer Res – volume: 3 start-page: e375 issue: 12 year: 2005 ident: 3912_CR29 publication-title: PLoS Biol doi: 10.1371/journal.pbio.0030375 – volume: 94 start-page: 2264 issue: 11 year: 2012 ident: 3912_CR97 publication-title: Biochimie doi: 10.1016/j.biochi.2012.05.012 – volume: 1790 start-page: 495 issue: 6 year: 2009 ident: 3912_CR16 publication-title: Biochem Biophys Acta doi: 10.1016/j.bbagen.2009.01.014 – volume: 94 start-page: 3633 issue: 8 year: 1997 ident: 3912_CR54 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.94.8.3633 – volume: 87 start-page: 8282 issue: 21 year: 1990 ident: 3912_CR70 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.87.21.8282 – ident: 3912_CR47 doi: 10.1007/s13402-018-00421-z – volume: 178 start-page: 179 issue: 1 year: 1996 ident: 3912_CR28 publication-title: Dev Biol doi: 10.1006/dbio.1996.0208 – volume: 104 start-page: 12288 issue: 30 year: 2007 ident: 3912_CR86 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0701549104 – volume: 274 start-page: 27891 issue: 39 year: 1999 ident: 3912_CR53 publication-title: J Biol Chem doi: 10.1074/jbc.274.39.27891 – volume: 17 start-page: 2596 issue: 9 year: 1998 ident: 3912_CR48 publication-title: EMBO J doi: 10.1093/emboj/17.9.2596 – volume: 9 start-page: 25 issue: 1 year: 2007 ident: 3912_CR18 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2007.9.25 – volume: 123 start-page: 1770 issue: 8 year: 2008 ident: 3912_CR71 publication-title: Int J Cancer doi: 10.1002/ijc.23709 – volume: 136 start-page: 1162 issue: 8 year: 2002 ident: 3912_CR117 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0704823 – volume: 133 start-page: 437 issue: 7 year: 2007 ident: 3912_CR126 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-006-0182-9 – volume: 5 start-page: 981 issue: 10 year: 2007 ident: 3912_CR99 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-07-0324 – volume: 18 start-page: 156 issue: 4 year: 2016 ident: 3912_CR44 publication-title: Iran J Dermatol – volume: 274 start-page: 35809 issue: 50 year: 1999 ident: 3912_CR56 publication-title: J Biol Chem doi: 10.1074/jbc.274.50.35809 – volume: 13 start-page: 21 issue: 1 year: 2004 ident: 3912_CR107 publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.13.1.21 – volume: 3 start-page: 206 issue: 11 year: 2017 ident: 3912_CR43 publication-title: Casp J Neurol Sci doi: 10.29252/nirp.cjns.3.11.206 – volume: 281 start-page: 1680 issue: 5383 year: 1998 ident: 3912_CR74 publication-title: Science doi: 10.1126/science.281.5383.1680 – volume: 11 start-page: 559 issue: 3 year: 2004 ident: 3912_CR130 publication-title: Oncol Rep – volume: 273 start-page: 10835 issue: 18 year: 1998 ident: 3912_CR87 publication-title: J Biol Chem doi: 10.1074/jbc.273.18.10835 – volume: 55 start-page: 987 issue: 7 year: 1998 ident: 3912_CR90 publication-title: Biochem Pharmacol doi: 10.1016/S0006-2952(97)00597-2 – volume: 54 start-page: 237 issue: 1 year: 1985 ident: 3912_CR19 publication-title: Annu Rev Biochem doi: 10.1146/annurev.bi.54.070185.001321 – volume: 16 start-page: 452 issue: 6 year: 2006 ident: 3912_CR15 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2006.09.004 – volume: 183 start-page: 287 issue: 2 year: 2014 ident: 3912_CR3 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbabio.2013.11.007 – volume: 429 start-page: 123 issue: 2 year: 2004 ident: 3912_CR52 publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2004.04.020 – volume: 12 start-page: 153 issue: 2 year: 2015 ident: 3912_CR101 publication-title: J Geriatr Cardiol – volume: 62 start-page: 5089 issue: 17 year: 2002 ident: 3912_CR13 publication-title: Cancer Res – volume: 7 start-page: 1189 issue: 9–10 year: 2005 ident: 3912_CR60 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2005.7.1189 – volume: 67 start-page: 689 issue: 4 year: 2004 ident: 3912_CR118 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2003.09.038 – volume: 53 start-page: 87 issue: 1 year: 2009 ident: 3912_CR14 publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.200700492 – volume: 90 start-page: 1259 issue: 12 year: 2002 ident: 3912_CR50 publication-title: Circ Res doi: 10.1161/01.RES.0000022160.64355.62 – volume: 42 start-page: 872 issue: 6 year: 2007 ident: 3912_CR116 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2006.12.021 – volume: 893 start-page: 13 issue: 1 year: 1999 ident: 3912_CR37 publication-title: Ann NY Acad Sci doi: 10.1111/j.1749-6632.1999.tb07814.x – volume: 99 start-page: 11700 issue: 18 year: 2002 ident: 3912_CR83 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.182372299 – volume: 10 start-page: 219 issue: 2–3 year: 1999 ident: 3912_CR128 publication-title: BioFactors doi: 10.1002/biof.5520100220 – volume: 92 start-page: 1210 issue: 15 year: 2000 ident: 3912_CR98 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.15.1210 – volume: 102 start-page: 673 issue: 3 year: 2005 ident: 3912_CR109 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0408732102 – volume: 346 start-page: 1 issue: Pt 1 year: 2000 ident: 3912_CR22 publication-title: Biochem J doi: 10.1042/bj3460001 – volume: 62 start-page: 3893 issue: 14 year: 2002 ident: 3912_CR125 publication-title: Cancer Res – volume: 4 start-page: 307 issue: 4 year: 2005 ident: 3912_CR132 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd1691 – ident: 3912_CR41 doi: 10.1002/jcb.28007 – volume: 281 start-page: 10691 issue: 16 year: 2006 ident: 3912_CR84 publication-title: J Biol Chem doi: 10.1074/jbc.M511373200 – ident: 3912_CR124 doi: 10.1155/2008/260146 – volume: 279 start-page: L1005 issue: 6 year: 2000 ident: 3912_CR2 publication-title: Am J Phys Lung Cell Mol Phys – volume: 7 start-page: 4765 issue: 8 year: 2014 ident: 3912_CR91 publication-title: Int J Clin Exp Pathol – volume: 273 start-page: 20096 issue: 32 year: 1998 ident: 3912_CR115 publication-title: J Biol Chem doi: 10.1074/jbc.273.32.20096 – volume: 268 start-page: 405 issue: 2 year: 2001 ident: 3912_CR11 publication-title: FEBS J – volume: 6 start-page: 312 issue: 4 year: 2018 ident: 3912_CR40 publication-title: Arch Bone Jt Surg – volume: 1 start-page: 194 issue: 3 year: 2001 ident: 3912_CR106 publication-title: Nat Rev Cancer doi: 10.1038/35106079 – volume: 18 start-page: 1165 issue: 10 year: 2013 ident: 3912_CR17 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2011.4322 – volume: 7 start-page: 392 issue: 4 year: 2007 ident: 3912_CR55 publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2007.04.003 – volume: 983 start-page: 84 issue: 1 year: 2003 ident: 3912_CR100 publication-title: Ann NY Acad Sci doi: 10.1111/j.1749-6632.2003.tb05964.x – volume: 2 start-page: 209 issue: 2 year: 2010 ident: 3912_CR5 publication-title: Cancers doi: 10.3390/cancers2020209 – volume: 14 start-page: 237 year: 2018 ident: 3912_CR78 publication-title: Redox Biol doi: 10.1016/j.redox.2017.09.014 – volume: 125 start-page: 1045 issue: 5 year: 2005 ident: 3912_CR108 publication-title: J Investig Dermatol doi: 10.1111/j.0022-202X.2005.23925.x – volume: 2 start-page: 235 issue: 3 year: 2003 ident: 3912_CR95 publication-title: Mol Cancer Ther – volume: 14 start-page: 428 issue: 2 year: 2018 ident: 3912_CR68 publication-title: J Cancer Res Ther doi: 10.4103/0973-1482.189229 – ident: #cr-split#-3912_CR42.1 – volume: 1218 start-page: 292 issue: 3 year: 1994 ident: 3912_CR4 publication-title: Biochim Biophys Acta doi: 10.1016/0167-4781(94)90180-5 – volume: 19 start-page: 285 issue: 5 year: 2003 ident: 3912_CR82 publication-title: Cell Biol Toxicol doi: 10.1023/B:CBTO.0000004952.07979.3d – volume: 56 start-page: 5765 issue: 24 year: 1996 ident: 3912_CR72 publication-title: Cancer Res – volume: 52 start-page: 29 issue: 1 year: 2001 ident: 3912_CR65 publication-title: IUBMB Life doi: 10.1080/15216540252774739 – volume: 12 start-page: 1247 issue: 10 year: 2007 ident: 3912_CR103 publication-title: Oncologist doi: 10.1634/theoncologist.12-10-1247 – volume: 23 start-page: 101 issue: 1 year: 2008 ident: 3912_CR113 publication-title: Histol Histopathol – volume: 74 start-page: 992 issue: 7 year: 2007 ident: 3912_CR119 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2007.07.022 – volume: 31 start-page: 1170 issue: 10 year: 2001 ident: 3912_CR133 publication-title: Free Radic Biol Med doi: 10.1016/S0891-5849(01)00698-0 – volume: 49 start-page: 1617 issue: 11 year: 2010 ident: 3912_CR57 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2010.09.005 – volume: 104 start-page: 11609 issue: 28 year: 2007 ident: 3912_CR51 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0704898104 – volume: 5 start-page: 2958 year: 2014 ident: 3912_CR62 publication-title: Nat Commun doi: 10.1038/ncomms3958 – ident: 3912_CR69 – volume: 12 start-page: 659 issue: 8 year: 1997 ident: 3912_CR85 publication-title: Anticancer Drug Des – volume: 147 start-page: 83 issue: 2 year: 2006 ident: 3912_CR93 publication-title: J Lab Clin Med doi: 10.1016/j.lab.2005.09.001 – volume: 66 start-page: 4410 issue: 8 year: 2006 ident: 3912_CR134 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3310 – volume: 9 start-page: 351 issue: 6–7 year: 1997 ident: 3912_CR92 publication-title: Oncol Res Featur Preclin Clin Cancer Ther – volume: 39 start-page: 696 issue: 5 year: 2005 ident: 3912_CR89 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2005.04.025 – volume: 160 start-page: 1 issue: 1 year: 2006 ident: 3912_CR38 publication-title: Chem Biol Interact doi: 10.1016/j.cbi.2005.12.009 – volume: 44 start-page: 14528 issue: 44 year: 2005 ident: 3912_CR27 publication-title: Biochemistry doi: 10.1021/bi051321w – volume: 45 start-page: 35 issue: 1 year: 2016 ident: 3912_CR45 publication-title: J Oral Pathol Med doi: 10.1111/jop.12326 – volume: 17 start-page: 21 issue: 1 year: 2016 ident: 3912_CR46 publication-title: J Dent – volume: 142 start-page: 46 issue: 1 year: 2003 ident: 3912_CR9 publication-title: Transl Res – volume: 2 start-page: 235 issue: 3 year: 2003 ident: 3912_CR94 publication-title: Mol Cancer Ther – volume: 423 start-page: 218 issue: 1 year: 2004 ident: 3912_CR12 publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2003.12.026 – volume: 189 start-page: 1783 issue: 11 year: 1999 ident: 3912_CR59 publication-title: J Exp Med doi: 10.1084/jem.189.11.1783 – volume: 96 start-page: 653 issue: 3 year: 2005 ident: 3912_CR77 publication-title: J Cell Biochem doi: 10.1002/jcb.20585 – volume: 48 start-page: 173 issue: 2 year: 2013 ident: 3912_CR25 publication-title: Crit Rev Biochem Mol Biol doi: 10.3109/10409238.2013.764840 – ident: 3912_CR26 – volume: 44 start-page: 1867 issue: 6 year: 2005 ident: 3912_CR114 publication-title: Inorg Chem doi: 10.1021/ic048260v – volume: 99 start-page: 2589 issue: 9 year: 1999 ident: 3912_CR112 publication-title: Chem Rev doi: 10.1021/cr980431o – volume: 24 start-page: 53 issue: 1 year: 2000 ident: 3912_CR8 publication-title: Cancer Detect Prev – volume: 6 start-page: 689 year: 1820 ident: 3912_CR32 publication-title: Biochim Biophysica Acta – volume: 291 start-page: 474 issue: 2 year: 2003 ident: 3912_CR79 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2003.07.005 – volume: 105 start-page: 1598 issue: 4 year: 2005 ident: 3912_CR61 publication-title: Blood doi: 10.1182/blood-2004-04-1577 – volume: 95 start-page: 3003 issue: 6 year: 1998 ident: 3912_CR102 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.95.6.3003 – volume: 272 start-page: 30615 issue: 49 year: 1997 ident: 3912_CR76 publication-title: J Biol Chem doi: 10.1074/jbc.272.49.30615 – volume: 14 start-page: 593 issue: 6 year: 2003 ident: 3912_CR127 publication-title: J Am Soc Mass Spectrom doi: 10.1016/S1044-0305(03)00141-7 – volume-title: On the potential of thioredoxin reductase inhibitors for cancer therapy. Seminars in cancer biology year: 2006 ident: 3912_CR131 – volume-title: The thioredoxin system in cancer. Seminars in cancer biology year: 2006 ident: 3912_CR10 – ident: 3912_CR110 doi: 10.1074/jbc.M512719200 – volume: 31 start-page: 1287 issue: 11 year: 2001 ident: 3912_CR1 publication-title: Free Radic Biol Med doi: 10.1016/S0891-5849(01)00724-9 – volume: 276 start-page: 31567 issue: 34 year: 2001 ident: 3912_CR24 publication-title: J Biol Chem doi: 10.1074/jbc.M101760200 – volume: 22 start-page: 3089 issue: 14_suppl year: 2004 ident: 3912_CR96 publication-title: J Clin Oncol doi: 10.1200/jco.2004.22.14_suppl.3089 – volume: 18 start-page: 259 issue: 3 year: 2013 ident: 3912_CR33 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2012.4716 – volume: 7 start-page: 211 issue: 4 year: 2018 ident: 3912_CR136 publication-title: J Herbmed Pharmacol doi: 10.15171/jhp.2018.33 – ident: 3912_CR137 doi: 10.1002/ptr.6236 – volume: 88 start-page: 1052 issue: 3 year: 1996 ident: 3912_CR121 publication-title: Blood doi: 10.1182/blood.V88.3.1052.1052 – ident: 3912_CR135 doi: 10.1002/jcp.27192 – volume: 39 start-page: 687 issue: 7 year: 2005 ident: 3912_CR88 publication-title: Free Radic Res doi: 10.1080/10715760500135391 – volume: 280 start-page: 25284 issue: 26 year: 2005 ident: 3912_CR138 publication-title: J Biol Chem doi: 10.1074/jbc.M414645200 – volume: 16 start-page: 3459 issue: 6B year: 1996 ident: 3912_CR81 publication-title: Anticancer Res – volume: 267 start-page: 24161 issue: 34 year: 1992 ident: 3912_CR58 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)35742-9 – volume: 95 start-page: S2 issue: S1 year: 2006 ident: 3912_CR105 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603463 – volume: 18 start-page: 5581 issue: 39 year: 2012 ident: 3912_CR7 publication-title: World J Gastroenterol doi: 10.3748/wjg.v18.i39.5581 – volume: 98 start-page: 12920 issue: 23 year: 2001 ident: 3912_CR30 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.231472998 – volume: 23 start-page: 2425 issue: 3B year: 2003 ident: 3912_CR80 publication-title: Anticancer Res – volume: 6 start-page: 41 issue: 1 year: 2004 ident: 3912_CR66 publication-title: Antioxid Redox Signal doi: 10.1089/152308604771978336 – volume: 17 start-page: 479 issue: 5 year: 2010 ident: 3912_CR139 publication-title: Curr Med Chem doi: 10.2174/092986710790226165 – volume: 20 start-page: 3821 issue: 15 year: 1992 ident: 3912_CR73 publication-title: Nucl Acids Res doi: 10.1093/nar/20.15.3821 – volume: 74 start-page: 659 issue: 5 year: 2007 ident: 3912_CR104 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2007.04.007 – volume: 267 start-page: 6102 issue: 20 year: 2000 ident: 3912_CR20 publication-title: FEBS J – volume: 94 start-page: 1483 issue: 11 year: 2004 ident: 3912_CR49 publication-title: Circ Res doi: 10.1161/01.RES.0000130525.37646.a7 – ident: #cr-split#-3912_CR42.2 – volume: 7 start-page: 209 issue: 3 year: 2000 ident: 3912_CR111 publication-title: Pathophysiology doi: 10.1016/S0928-4680(00)00050-X – volume: 13 start-page: 540 issue: 4 year: 2002 ident: 3912_CR36 publication-title: AACN Adv Crit Care – volume: 24 start-page: 40 issue: 1 year: 2004 ident: 3912_CR21 publication-title: Med Res Rev doi: 10.1002/med.10051 – volume: 15 start-page: 351 year: 1997 ident: 3912_CR75 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.15.1.351 |
| SSID | ssj0004133 |
| Score | 2.5543582 |
| SecondaryResourceType | review_article |
| Snippet | Thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 925 |
| SubjectTerms | Animals Antineoplastic Agents - pharmacology Antineoplastic drugs Antioxidants Antioxidants - metabolism Antitumor activity Antitumor agents Apoptosis Apoptosis - drug effects Cancer Cancer Research Cancer therapies Chemotherapy Drug resistance Humans Medicine Medicine & Public Health NADP NADP - metabolism Neoplasms - drug therapy Neoplasms - pathology Oncology Oxidative stress Oxidative Stress - drug effects Pharmacology/Toxicology Reductase Review Article Thioredoxin Thioredoxin-Disulfide Reductase - metabolism Thioredoxins - metabolism Tumor cells Tumorigenesis |
| SummonAdditionalLinks | – databaseName: Springer LINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD6CgtBeNgZsdCvIkxAv1FISO7XDG5pAPEBVDVb1LfItohJKp17Q-u_nS5IKFSbBY-RjJzo-zjnW5-8zwElWUAcPeuifYMo4xUJGDNvclCpe6ML4w5jDG9bv89EoG1SksFl92r2GJP2fuiG7eRTQbn0z7FTNE0w3YcsOyd1y_HU3XLEh43CBPKEUpyyiFVXm5TGep6O1GnMNH_Vp5-rT-z54Fz5WZSa6CHHxGTZMuQc7txWQvgengyBZveyi-xUDa9ZFp2iwErNe7gOxzWj-MJ44YdG_4xIF6WckSo2Ui5gpChSu5TkSKBBhDuD31eX9z2tcXbSAFWHpHCvNZS-RjKaZTHTKpRCRZImWsX0udCxVIkyqeUxiSSJlK4IkItY8kkr3jE34X6BVTkpzCIja8sPuaKJISUONKKTsiYxyu3HKjE56ug1x7e9cVSrk7jKMx7zRT_Zuy63bcu-2nLbhrOnzJ2hw_Ne6U09jXq3HWW6LTOYg1oy34UfTbFeSg0dEaSaLYMMoTxlpw9cw_c3riFO2Y9z27tZzvRr89W_59jbz7_AhceHiqY4daM2nC3ME2-ppPp5Nj32U_wNVF_JI priority: 102 providerName: Springer Nature |
| Title | The thioredoxin system and cancer therapy: a review |
| URI | https://link.springer.com/article/10.1007/s00280-019-03912-4 https://www.ncbi.nlm.nih.gov/pubmed/31367788 https://www.proquest.com/docview/2267278498 https://www.proquest.com/docview/2267748573 |
| Volume | 84 |
| WOSCitedRecordID | wos000490601000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-0843 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004133 issn: 0344-5704 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LaxsxEB7yKCWXJk3b1ElqFAi51KJardbS5hKSkNBDa0yaBt8WvZYayjq1nVL_--plLyE0l14WhKTdYWckjfRpvgE4Lmvm4cEA_eeYccGwVIRjtzYVWtSmtuEy5t0XPhiI0agcpgO3WbpWuZwTw0RtJtqfkX9ybgL3IFkpzu5_YZ81yqOrKYXGOmxmlDA_MMVle8XDTdAxPTJjuOCEpaCZEDoXMEW3kS6x50inmD1emJ54m0-Q0rAAXW__r-g78Cq5nug82sprWLPNLrz8msD1XTgZRhrrRQ_dtlFZsx46QcOW4HrxBnJXjeY_xhNPNvpn3KBIB41kY5D2VjRFMaxrcYokisExb-H79dXt5Wecki9gnfNijrURqk8VZ0WpqCmEkpIoTo3KXLk2mdJU2sKILM9UTrTzEijJXXOitOlb5wS8g41m0tj3gJhzSdwuhxCtLLOyVqovSybcZqq0hvZNB7Lln690Yib3CTJ-VitO5aCtymmrCtqqWAc-rvrcR16OZ1sfLjVTpTE6q1q1dOBoVe1Gl4dMZGMnD7ENZ6LgeQf2oiGsPpd7tjsuXO_e0jLal_9blv3nZTmALeqtMoQ7HsLGfPpgP8AL_Xs-nk27sM5HPDxFN9h6FzYvrgbDG1e6-Xb3FzIuAMM |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED9NYwJe2BhfhQFGgr1Qi8R2amfShBAwbVpX9aGgvmX-iqiE0tF2bP2n-Bvnj6QRmtjbHniMbCdO_LuzL3f3O4C3ecm8ezC4_ilmXDAsVcKx25syLUpT2hCM-b3PBwMxHufDNfjT5ML4sMpGJwZFbaba_yP_4I4J3DvJcvHx7Bf2VaO8d7UpoRFhcWyXF85km-8ffXHr-46Qg6-jz4e4riqANeXZAmsjVI8ozrJcEZMJJWWiODEqddelSZUm0mZGpDRVNNFu-yMJdd0TpU3PCl8lwqn8O06Pcx9Cxse8zcNMY-l6yhjOeMLqJJ2Qqhd8mM5wz7HnZCeY_b0RXjvdXvPMhg3vYPN_-1Rb8KA-WqNPURYewpqttuHuSR08sA27w0jTveyiUZt1Nu-iXTRsCbyXj4C6ZrT4MZl6MtXLSYUi3TWSlUHaS8kMxbS15R6SKCb_PIZvt_JuT2C9mlb2GSDmjlzOiksSrSyzslSqJ3MmnLGYW0N6pgNps9KFrpnXfQGQn8WKMzqgo3DoKAI6CtaB96sxZ5F35MbeOw0SiloHzYsWBh14s2p22sO7hGRlp-exD2ci47QDTyPwVo-jns2PCze62yCxvfm_5_L85rm8hnuHo5N-0T8aHL-A-8RLREjt3IH1xezcvoQN_Xsxmc9eBdlCcHrbCL0ClK5aaA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LT9wwEB4hWqFe-qCvbaF1pZZL1yKxnbWDhFAFXRVBV3ug1d6CX1FXQlnYXVr2r_Hr6keyUYXgxqHHyHbixN-MPZmZbwA-5iXz7sHg-qeYccGwVAnHbm_KtChNaUMw5s9jPhiI0SgfrsB1kwvjwyobnRgUtZlo_4982x0TuHeS5WK7rMMihgf9vfML7CtIeU9rU04jQuTILv448222e3jg1voTIf2vJ_vfcF1hAGvKsznWRqgeUZxluSImE0rKRHFiVOquS5MqTaTNjEhpqmii3VZIEuq6J0qbnhW-YoRT_w84pdyXjeAj3uZkprGMPWUMZzxhdcJOSNsL_kxnxOfY87MTzP7dFG-cdG94acPm13_yP3-2p_C4PnKjL1FGnsGKrdZh7XsdVLAOW8NI373oopM2G23WRVto2BJ7L54Ddc1o_ms88SSrV-MKRRpsJCuDtJeeKYrpbIsdJFFMCnoBP-7l3V7CajWp7GtAzB3FnHWXJFpZZmWpVE_mTDgjMreG9EwH0mbVC10zsvvCIGfFkks6IKVwSCkCUgrWgc_LMeeRj-TO3hsNKopaN82KFhId-LBsdlrFu4pkZSeXsQ9nIuO0A68iCJePo57ljws3utugsr357XN5c_dc3sOaA2ZxfDg4eguPiBeOkPG5Aavz6aXdhIf693w8m74LYobg9L4B-he7i2Mc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+thioredoxin+system+and+cancer+therapy%3A+a+review&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Mohammadi%2C+Fariba&rft.au=Soltani%2C+Arash&rft.au=Ghahremanloo%2C+Atefeh&rft.au=Javid%2C+Hossein&rft.date=2019-11-01&rft.eissn=1432-0843&rft.volume=84&rft.issue=5&rft.spage=925&rft_id=info:doi/10.1007%2Fs00280-019-03912-4&rft_id=info%3Apmid%2F31367788&rft.externalDocID=31367788 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |